IMC-CS4

· Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for IMC-CS4, covering 2024-09-19 to 2024-10-15. Get the full timeline:

Most recent: Clinical Trial Update: Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas [EARLY_Phase 1]

See pricing